CONCORD HC GP
Listing Date | 2024/01/09 |
Listing Price | 14.280 |
- Subscription Rate1.99x
- Guarantee One Lot Size1 lot
- One Lot Success Rate100%
Listing Date | 2024/01/09 |
Listing Price | 14.280 |
Concord Healthcare Group is an oncology healthcare service provider in China serving both cancer patients and third-party medical institutions, with a market share of 0.5% in terms of revenue in 2022 in the private oncology healthcare service market in China, according to report.
--
The Group serves both cancer patients through its self-owned medical institutions and third-party medical institutions through its medical equipment, software and related services. As of December 19, 2023, it had six self-owned medical institutions in operation located in Guangzhou, Shanghai and Datong, including two cancer hospitals, three outpatient centers or clinic and one imaging diagnosis center, and an internet hospital. wo cancer hospitals, three outpatient centers or clinic and one imaging diagnosis center, and an internet hospital. It had one additional self-owned cancer hospital under construction in Shanghai. It is expected Guangzhou Hospital to commence the operation of its proton center and provide proton therapy services in 2024.
--
During the period comprising FY2020, FY2021, FY2022, 6M2022 and 6M2023, it served 29, 88, 77, 42 and 47 enterprise customers under its medical equipment, software and related services, respectively.
--
Its customers primarily include patients that receive oncology diagnosis and treatment services at its medical institutions, and enterprise customers, including primarily its partnered hospitals, other medical institutions and medical enterprises, as well as distributors, for its medical equipment, software and related services.
Market | Hong Kong (Main Board) |
Business Nature | Health Care |
Major Business Area | China |
Board Lot | 200 |
No. of Offer Shares | 39.42M H shares |
No. of International Offer Shares | 35.48M H shares |
No. of HK Offer Shares | 3.94M H shares |
Offer Price | $14.10 - $16.40 |
Stock Code | 2453 |
Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, Haitong International Capital Limited |
Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, Haitong International Securities Company Limited, CLSA Limited, SPDB International Capital Limited, ABCI Securities Company Limited, CCB International Capital Limited, China Everbright Securities (HK) Limited, CMB International Capital Limited, Fosun International Securities Limited, Futu Securities International (Hong Kong) Limited, Livermore Holdings Limited, Mouette Securities Company Limited, Valuable Capital Limited, Tiger Brokers (HK) Global Limited |
Application Period | Dec 29 (Fri) - noon, Jan 04 (Thu) |
Price Determination Date | Jan 05 (Fri) |
Result Announcement Date | On or before Jan 08 (Mon) |
Result Announcement Date | On or before Jan 08 (Mon) |
Result Announcement Date | On or before Jan 09 (Tue) |
Dealings in Shares commence on | Jan 09, 2024. (Tue) |
Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
% of total shares reallocated to HK Offer | 30% | 40% | 50% |
Offer Price | $14.10 - $16.40 |
Capitalization (H Shares) | 3.48B - 4.04B |
NAV / share ($) | $2.74 - $2.86 (Unaudited pro forma adj NAV / share) |
Assuming the offer price being at HKD 15.25, the net proceeds raised would be HKD 503.10M, of which |
59.4% : Repaying part of interest-bearing bank borrowings |
30.6% : Financing the construction of Shanghai Hospital |
10% : Working capital |
Prospectus | Chinese Version | English Version |
Remark: | The above information is referenced from the prospectus. |
All data is calculated from the non- exercise rights(if applicable). |
Currency | : |
Listing Price | : |
Board Lot | : |
Admission Fee* |
: |
Subscribing Lot | : |
Subscribing Fee | : |
Subscribing Amount | : |